Foley & Lardner LLP
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.
Memorial Sloan Kettering Cancer Center
A A A C C C A A A C C C C A C C
A61K A61K A61K C07K C12N C12N A61K A61P A61K C12N C07K C07K C12N A61K C07K C12N
additional inventional additional additional additional additional inventional inventional inventional inventional inventional inventional additional inventional inventional additional
Peihong Liang Stewart Ning Taha Jedd Weiyi
Dai Deng Shuman Yang Merghoub Wolchok Wang